158 related articles for article (PubMed ID: 38321099)
1. The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.
Aljuhani O; Al Sulaiman K; Korayem GB; Altebainawi AF; Alsohimi S; Alqahtani R; Alfaifi S; Alharbi A; AlKhayrat A; Hattan A; Albassam M; Almohammed OA; Alkeraidees A; Alonazi DA; Alsalman WF; Aldamegh G; Alshahrani R; Vishwakarma R
Sci Rep; 2024 Feb; 14(1):3037. PubMed ID: 38321099
[TBL] [Abstract][Full Text] [Related]
2. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
[No Abstract] [Full Text] [Related]
4. Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study.
Al Harbi S; Kensara R; Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Vishwakarma R; Alenazi AM; Almutairi A; Alshaya O; Alraddadi S; Al Sulaiman T; Aldakkan L; Mahboob R; Alaamer K; Alissa A; Hafiz A; Aldhayyan N; Althewaibi S; Alenezi F; Alkhotani NY; Alghamdi SA; Alenazi AA; Al Sulaiman K
Clin Appl Thromb Hemost; 2022; 28():10760296221103864. PubMed ID: 35658686
[TBL] [Abstract][Full Text] [Related]
5. The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study.
Korayem GB; Aljuhani O; Altebainawi AF; Shaya AIA; Alnajjar LI; Alissa A; Aldhaeefi M; Kensara R; Al Muqati H; Alhuwahmel A; Alhuthaili O; Vishwakarma R; Aldardeer N; Eljaaly K; Alharbi A; Harbi SA; Katheri AA; Bekairy AMA; Aljedai A; Al Sulaiman K
Int J Infect Dis; 2022 Sep; 122():252-259. PubMed ID: 35605948
[TBL] [Abstract][Full Text] [Related]
6. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics.
Elhazmi A; Rabie AA; Al-Omari A; Mufti HN; Sallam H; Alshahrani MS; Mady A; Alghamdi A; Altalaq A; Azzam MH; Sindi A; Kharaba A; Al-Aseri ZA; Almekhlafi GA; Tashkandi W; Alajmi SA; Faqihi F; Alharthy A; Al-Tawfiq JA; Melibari RG; Arabi YM
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983304
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.
Al Sulaiman K; Aljuhani O; Al Dossari M; Alshahrani A; Alharbi A; Algarni R; Al Jeraisy M; Al Harbi S; Al Katheri A; Al Eidan F; Al Bekairy AM; Al Qahtani N; Al Muqrin M; Vishwakarma R; Al Ghamdi G
Crit Care; 2021 Jun; 25(1):223. PubMed ID: 34193235
[TBL] [Abstract][Full Text] [Related]
9. Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study.
Al Sulaiman K; Aljuhani O; Bin Salah K; Korayem GB; Eljaaly K; Al Essa M; Kharbosh A; Al Harbi F; Abuzaid M; Al Bilal S; Almagthali A; Alsohemi S; Alshabasy A; Noureldeen H; Aboudeif M; Alshehri A; Vishwakarma R
J Crit Care; 2021 Dec; 66():44-51. PubMed ID: 34438133
[TBL] [Abstract][Full Text] [Related]
10. The use of Tocilizumab in COVID-19 critically ill patients with renal impairment: a multicenter, cohort study.
Aljuhani O; Al Sulaiman K; B Korayem G; Alharbi A; Altebainawi AF; Aldkheel SA; Alotaibi SG; Vishwakarma R; Alshareef H; Alsohimi S; AlFaifi M; Al Shaya A; Alhaidal HA; Alsubaie RM; Alrashidi H; Albarqi KJ; Alangari DT; Alanazi RM; Altaher NM; Al-Dorzi HM
Ren Fail; 2023; 45(2):2268213. PubMed ID: 37870869
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.
Al Harthi AF; Aljuhani O; Korayem GB; Altebainawi AF; Alenezi RS; Al Harbi S; Gramish J; Kensara R; Hafidh A; Al Enazi H; Alawad A; Alotaibi R; Alshehri A; Alhuthaili O; Vishwakarma R; Bin Saleh K; Alsulaiman T; Alqahtani RA; Hussain S; Almazrou S; Al Sulaiman K
J Intensive Care Med; 2022 Sep; 37(9):1238-1249. PubMed ID: 35450493
[TBL] [Abstract][Full Text] [Related]
12. Doxycycline's Potential Role in Reducing Thrombosis and Mortality in Critically Ill Patients With COVID-19: A Multicenter Cohort Study.
Al Sulaiman K; Aljuhani O; Korayem GB; Alnajjar LI; Altebainawi AF; AlFaifi M; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Alsowaida YS; Alsohimi S; Almagthali A; Alay SM; Altaher N; Alamri MG; Alangari D; Alzahrani A; Abdul Razack HI; Alhamoud J; Alshaya A; Gramish J; Al Aamer K; Alsaeedi AS; Alghamdi G
Clin Appl Thromb Hemost; 2023; 29():10760296231177017. PubMed ID: 37322869
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study.
Al Sulaiman K; Korayem GB; Altebainawi AF; Al Harbi S; Alissa A; Alharthi A; Kensara R; Alfahed A; Vishwakarma R; Al Haji H; Almohaimid N; Al Zumai O; Alrubayan F; Asiri A; Alkahtani N; Alolayan A; Alsohimi S; Melibari N; Almagthali A; Aljahdali S; Alenazi AA; Alsaeedi AS; Al Ghamdi G; Al Faris O; Alqahtani J; Al Qahtani J; Alshammari KA; Alshammari KI; Aljuhani O
Crit Care; 2022 Oct; 26(1):304. PubMed ID: 36192801
[TBL] [Abstract][Full Text] [Related]
14. When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study.
Al Sulaiman K; Aljuhani O; Korayem GB; Altebainawi AF; AlFaifi M; Nahari M; Almagthali A; Thabit AK; Alhajaji R; Alharbi R; Kahtani K; Alenazi AA; Alharbi A; Alghwainm MM; Alotaibi SM; Alghamdi YS; Alotaibi S; Alonazi SH; Almutairi JM; Vishwakarma R
J Infect Public Health; 2023 Sep; 16(9):1492-1499. PubMed ID: 37355406
[TBL] [Abstract][Full Text] [Related]
15. Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study.
Al Sulaiman K; Aljuhani O; Korayem GB; Hafiz A; Alalawi M; Badreldin HA; Altebainawi AF; Vishwakarma R; Alissa A; Alghamdi A; Alenazi AA; Al Enazi H; Alanazi S; Alhammad A; Alghamdi J; AlFaifi M; Al Sehli FA; Aldossari MA; Alhubaishi AA; Al-Ali AY; Al-Dorzi HM
Thromb J; 2022 Dec; 20(1):74. PubMed ID: 36482388
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab: A retrospective multi-center cohort study of critically ill patients with COVID-19.
Villatoro Santos CR; Bhargava A; Coyle M; Szpunar S; Saravolatz LD
Int J Clin Pharmacol Ther; 2021 Nov; 59(11):705-712. PubMed ID: 34448693
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
[TBL] [Abstract][Full Text] [Related]
19. Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study.
Aljuhani O; Al Sulaiman K; Alshabasy A; Eljaaly K; Al Shaya AI; Noureldeen H; Aboudeif M; Al Dosari B; Alkhalaf A; Korayem GB; Aleissa MM; Badreldin HA; Al Harbi S; Alhammad A; Vishwakarma R
BMC Infect Dis; 2021 Nov; 21(1):1127. PubMed ID: 34724920
[TBL] [Abstract][Full Text] [Related]
20. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
Med Clin (Barc); 2022 Apr; 158(7):301-307. PubMed ID: 34147248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
